Supplemental Materials for

Prognostic Ability of PD-L1 Levels in Urothelial Carcinoma Patients– A meta-analysis

J Huang, MD, X Teng, MD

List of supplementary files:

Supplementary table 2

Supplementary table 3

Corresponding author
Dr Xiaodong Teng
Department of Pathology
The First Affiliated Hospital,

College of Medicine, Zhejiang University

79 Qingchun Road, Hangzhou, China.

E-mail ID: teng.xiaodong@yahoo.com
Telephone: 86-13867484836

Supplementary table 2. PD-L1 testing methodology and prevalence of PD-L1 in the included studies.

S.No.	Author	Year	PD-L1 Assay developer	Antibody clone used for IHC	Target cell population Tumor cell (TC)/ Immune cell (IC)	Expression threshold of PDL1	PD-L1 positive	PD-L1 negative
1	Balar AV	2017	Agilent	22C3	TC and IC	10%	30%	70%
						1%	83%	17%
2	Sharma P	2017	Dako	28-8	TC	1%	46%	54%
						5%	31%	69%
3	Pal SK	2018	Ventana	SP142	IC	5%	52%	48%
4	Plimack ER	2017	Dako	22C3	TC and IC	1%	84%	16%
5	Sharma P	2016	Dako	28-8	TC	1%	37%	63%
6	Perez-Gracia JL	2017	Ventana	SP142	IC	1%	67%	33%
						5%	32%	68%
7	Petrylak	2018	Ventana	SPI142	IC	5%	53%	7%

8	Powles	2017	Ventana	SP-263	IC or TC	25%	55%	45%
9	Apolo	2018	Dako	73-10	TC	5%	45%	55%
10	Balar et al.,	2017	Ventana	SPI142	IC	1%	67%	33%
						5%	27%	73%

Supplementary table 3. Diagnostic characteristics of the 3 PD-L1 thresholds.

Diagnostic characteristic	1% PD-L1 threshold value	95%CI	≥5% PD-L1 threshold value	95%CI	≥25% PD-L1 threshold value	95%CI
Sensitivity	73.04%	66.4% to 79%	52.59%	45.95% to 59.16%	87.10%	70.17% to 96.37%
Specificity	39.62%	36.18% to 43.14%	70.41 %	67.31% to 73.38%	51.37 %	42.97% to 59.72%
Positive predictive value	1.21	1.09 to 1.34	1.78	1.52 to 2.08	1.79	1.44 to 2.22
Negative predictive value	0.68	0.53 to 0.87	0.67	0.58 to 0.78	0.25	0.10 to 0.64